Published in J Acquir Immune Defic Syndr on October 01, 2010
The evolution of HIV: inferences using phylogenetics. Mol Phylogenet Evol (2011) 0.94
Phylodynamics of the HIV-1 epidemic in Cuba. PLoS One (2013) 0.89
Phylogenetic relatedness of circulating HIV-1C variants in Mochudi, Botswana. PLoS One (2013) 0.88
Evolutionary history of HIV-1 subtype B and CRF01_AE transmission clusters among men who have sex with men (MSM) in Kuala Lumpur, Malaysia. PLoS One (2013) 0.87
Spatiotemporal dynamics of dissemination of non-pandemic HIV-1 subtype B clades in the Caribbean region. PLoS One (2014) 0.86
Phylogeny and phylodinamic of Hepatitis C in Italy. BMC Infect Dis (2012) 0.84
Human immunodeficiency virus type 1 (HIV-1) subtype B epidemic in Panama is mainly driven by dissemination of country-specific clades. PLoS One (2014) 0.84
The Use of Bioinformatics for Studying HIV Evolutionary and Epidemiological History in South America. AIDS Res Treat (2011) 0.81
Phylodynamic profile of HIV-1 subtype B, CRF01_AE and the recently emerging CRF51_01B among men who have sex with men (MSM) in Singapore. PLoS One (2013) 0.80
Full-genome characterization of a G8P[8] rotavirus that emerged among children with diarrhea in Croatia in 2006. J Clin Microbiol (2013) 0.78
Phylogeny and Phylogeography of a Recent HIV-1 Subtype F Outbreak among Men Who Have Sex with Men in Spain Deriving from a Cluster with a Wide Geographic Circulation in Western Europe. PLoS One (2015) 0.78
Bridging epidemiology with population genetics in a low incidence MSM-driven HIV-1 subtype B epidemic in Central Europe. BMC Infect Dis (2015) 0.77
Co-infections and transmission networks of HCV, HIV-1 and HPgV among people who inject drugs. Sci Rep (2015) 0.77
High Prevalence and Onward Transmission of Non-Pandemic HIV-1 Subtype B Clades in Northern and Northeastern Brazilian Regions. PLoS One (2016) 0.77
Transmission Networks of HIV-1 Among Men Who Have Sex With Men in East and Southeast Asia. J Acquir Immune Defic Syndr (2015) 0.75
Multiple introductions and onward transmission of non-pandemic HIV-1 subtype B strains in North America and Europe. Sci Rep (2016) 0.75
Short-Term Dynamic and Local Epidemiological Trends in the South American HIV-1B Epidemic. PLoS One (2016) 0.75
Time-scale of minor HIV-1 complex circulating recombinant forms from Central and West Africa. BMC Evol Biol (2016) 0.75
Phylodynamic and Phylogeographic Profiles of Subtype B HIV-1 Epidemics in South Spain. PLoS One (2016) 0.75
Interrupting transmission of HIV and other sexually transmitted infections in Rhode Island. Med Health R I (2012) 0.75
Spatio-Temporal History of HIV-1 CRF35_AD in Afghanistan and Iran. PLoS One (2016) 0.75
The molecular epidemiology of HIV-1 in the Comunidad Valenciana (Spain): analysis of transmission clusters. Sci Rep (2017) 0.75
Molecular epidemiology: HIV-1 and HCV sequences from Libyan outbreak. Nature (2006) 2.61
Microbial translocation predicts disease progression of HIV-infected antiretroviral-naive patients with high CD4+ cell count. AIDS (2011) 2.45
Mutations in HIV-1 reverse transcriptase potentially associated with hypersusceptibility to nonnucleoside reverse-transcriptase inhibitors: effect on response to efavirenz-based therapy in an urban observational cohort. J Infect Dis (2004) 2.21
Relationship between HAART adherence and adipose tissue alterations. J Acquir Immune Defic Syndr (2002) 1.97
Stable changes in CD4+ T lymphocyte miRNA expression after exposure to HIV-1. Blood (2012) 1.89
Safety of complete and sustained prophylaxis withdrawal in patients liver-transplanted for HBV-related cirrhosis at low risk of HBV recurrence. J Hepatol (2011) 1.74
Analysis of single-nucleotide polymorphisms (SNPs) in human CYP3A4 and CYP3A5 genes: potential implications for the metabolism of HIV drugs. BMC Med Genet (2014) 1.58
Role of hepatitis B virus genetic barrier in drug-resistance and immune-escape development. Dig Liver Dis (2011) 1.57
Macrophages and HIV infection: therapeutical approaches toward this strategic virus reservoir. Antiviral Res (2002) 1.57
Point-of-care screening, prevalence, and risk factors for hepatitis B infection among 3,728 mainly undocumented migrants from non-EU countries in northern Italy. J Travel Med (2014) 1.54
Factors influencing virological response to antiretroviral drugs in cerebrospinal fluid of advanced HIV-1-infected patients. AIDS (2002) 1.54
Host immunogenetics and control of human herpesvirus-8 infection. J Infect Dis (2006) 1.52
Low-dose prolonged intermittent interleukin-2 adjuvant therapy: results of a randomized trial among human immunodeficiency virus-positive patients with advanced immune impairment. J Infect Dis (2002) 1.52
Total and covalently closed circular DNA detection in liver tissue of long-term survivors transplanted for HBV-related cirrhosis. Dig Liver Dis (2010) 1.51
Reliability and clinical relevance of the HIV-1 drug resistance test in patients with low viremia levels. Clin Infect Dis (2014) 1.47
Variable prediction of antiretroviral treatment outcome by different systems for interpreting genotypic human immunodeficiency virus type 1 drug resistance. J Infect Dis (2003) 1.47
The profile of mutational clusters associated with lamivudine resistance can be constrained by HBV genotypes. J Hepatol (2008) 1.45
Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update December 2014. New Microbiol (2015) 1.45
The clinical appearance of pinta mimics secondary syphilis: another trap of treponematosis? Clin Infect Dis (2005) 1.42
Performance of the preliminary classification criteria for cryoglobulinaemic vasculitis and clinical manifestations in hepatitis C virus-unrelated cryoglobulinaemic vasculitis. Clin Exp Rheumatol (2012) 1.41
Risk of failure in patients with 215 HIV-1 revertants starting their first thymidine analog-containing highly active antiretroviral therapy. AIDS (2004) 1.40
Comparative analysis of T-cell turnover and homeostatic parameters in HIV-infected patients with discordant immune-virological responses to HAART. AIDS (2006) 1.40
Role of individual's T-cell immunome in controlling HIV-1 progression. Immunology (2014) 1.39
Efficacy of cerebrospinal fluid (CSF)-penetrating antiretroviral drugs against HIV in the neurological compartment: different patterns of phenotypic resistance in CSF and plasma. Clin Infect Dis (2005) 1.35
The cooperative induction of hypoxia-inducible factor-1 alpha and STAT3 during hypoxia induced an impairment of tumor susceptibility to CTL-mediated cell lysis. J Immunol (2009) 1.32
High-resolution molecular epidemiology and evolutionary history of HIV-1 subtypes in Albania. PLoS One (2008) 1.30
Late presenters in new HIV diagnoses from an Italian cohort of HIV-infected patients: prevalence and clinical outcome. Antivir Ther (2011) 1.30
A novel methodology for large-scale phylogeny partition. Nat Commun (2011) 1.29
Involvement of novel human immunodeficiency virus type 1 reverse transcriptase mutations in the regulation of resistance to nucleoside inhibitors. J Virol (2006) 1.28
Increased mitochondrial DNA content in peripheral blood lymphocytes from HIV-infected patients with lipodystrophy. Antivir Ther (2003) 1.26
Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients. Autoimmun Rev (2011) 1.26
High sequence conservation of human immunodeficiency virus type 1 reverse transcriptase under drug pressure despite the continuous appearance of mutations. J Virol (2005) 1.24
The presence of anti-Tat antibodies is predictive of long-term nonprogression to AIDS or severe immunodeficiency: findings in a cohort of HIV-1 seroconverters. J Infect Dis (2005) 1.23
Novel human immunodeficiency virus type 1 protease mutations potentially involved in resistance to protease inhibitors. Antimicrob Agents Chemother (2005) 1.23
Membrane-bound and soluble IL-15/IL-15Ralpha complexes display differential signaling and functions on human hematopoietic progenitors. Blood (2005) 1.22
Inter- and intra-patient variability of raltegravir pharmacokinetics in HIV-1-infected subjects. J Antimicrob Chemother (2011) 1.22
Construction, training and clinical validation of an interpretation system for genotypic HIV-1 drug resistance based on fuzzy rules revised by virological outcomes. Antivir Ther (2004) 1.21
Anti-HIV effects of chloroquine: inhibition of viral particle glycosylation and synergism with protease inhibitors. J Acquir Immune Defic Syndr (2004) 1.21
Thrombotic microangiopathy in patients with acquired immunodeficiency syndrome before and during the era of introduction of highly active antiretroviral therapy. Clin Infect Dis (2002) 1.17
HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors. PLoS One (2012) 1.17
The novel KI, WU, MC polyomaviruses: possible human pathogens? New Microbiol (2011) 1.16
Therapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAART. PLoS One (2010) 1.13
Drug resistance among drug-naive and first-line antiretroviral treatment-failing children in Cameroon. Pediatr Infect Dis J (2011) 1.13
Prevalence and type distribution of high-risk human papillomavirus infection in women undergoing voluntary cervical cancer screening in Italy. J Med Virol (2009) 1.12
Prevalence, genotype diversity and determinants of anal HPV infection in HIV-uninfected men having sex with men. J Clin Virol (2012) 1.12
Excretion of the novel polyomaviruses KI and WU in the stool of patients with hematological disorders. J Med Virol (2009) 1.11
Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatment. J Antimicrob Chemother (2006) 1.11
HIV-1 Genetic Variability and Clinical Implications. ISRN Microbiol (2013) 1.10
Detection of Toscana virus central nervous system infections in Sardinia Island, Italy. J Clin Virol (2007) 1.10
Performance of genotypic tropism testing on proviral DNA in clinical practice: results from the DIVA study group. New Microbiol (2012) 1.10
Vpr and HIV-1 disease progression: R77Q mutation is associated with long-term control of HIV-1 infection in different groups of patients. AIDS (2006) 1.09
Study of genotypic and phenotypic HIV-1 dynamics of integrase mutations during raltegravir treatment: a refined analysis by ultra-deep 454 pyrosequencing. J Infect Dis (2012) 1.09
The HIV type 1 epidemic in Bulgaria involves multiple subtypes and is sustained by continuous viral inflow from West and East European countries. AIDS Res Hum Retroviruses (2008) 1.07
Severe acute respiratory syndrome coronavirus sequence characteristics and evolutionary rate estimate from maximum likelihood analysis. J Virol (2004) 1.07
Performance of genotypic tropism testing in clinical practice using the enhanced sensitivity version of Trofile as reference assay: results from the OSCAR Study Group. New Microbiol (2010) 1.06
A multicenter evaluation of the Abbott RealTime HCV Genotype II assay. J Virol Methods (2010) 1.06
Genetic polymorphisms differently influencing the emergence of atrophy and fat accumulation in HIV-related lipodystrophy. AIDS (2008) 1.05
Evaluation of the Abbott RealTime HBV DNA assay and comparison to the Cobas AmpliPrep/Cobas TaqMan 48 assay in monitoring patients with chronic cases of hepatitis B. J Clin Microbiol (2008) 1.04
Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors. Antimicrob Agents Chemother (2010) 1.04
Epidemiological network analysis in HIV-1 B infected patients diagnosed in Italy between 2000 and 2008. Infect Genet Evol (2011) 1.04
Therapeutic drug monitoring and drug-drug interactions involving antiretroviral drugs. Antivir Ther (2005) 1.04
Epidemiological history and phylogeography of West Nile virus lineage 2. Infect Genet Evol (2013) 1.03
Trends in the postmortem diagnosis of opportunistic invasive fungal infections in patients with AIDS: a retrospective study of 1,630 autopsies performed between 1984 and 2002. Am J Clin Pathol (2009) 1.03
Different evolution of genotypic resistance profiles to emtricitabine versus lamivudine in tenofovir-containing regimens. J Acquir Immune Defic Syndr (2010) 1.03
Origin of the 2009 Mexico influenza virus: a comparative phylogenetic analysis of the principal external antigens and matrix protein. Arch Virol (2009) 1.02
Aspergillus meningitis: a rare clinical manifestation of central nervous system aspergillosis. Case report and review of 92 cases. J Infect (2012) 1.02
Mechanisms underlying activity of antiretroviral drugs in HIV-1-infected macrophages: new therapeutic strategies. J Leukoc Biol (2006) 1.02
Origin, evolution, and phylogeography of recent epidemic CHIKV strains. Infect Genet Evol (2012) 1.02
Long-term protection against SHIV89.6P replication in HIV-1 Tat vaccinated cynomolgus monkeys. Vaccine (2004) 1.01
Clinorotation-induced weightlessness influences the cytoskeleton of glial cells in culture. Brain Res (2002) 1.01
Prospective observational study of fever in hospitalized returning travelers and migrants from tropical areas, 1997-2001. J Travel Med (2005) 1.00
Chikungunya and dengue viruses in travelers. Emerg Infect Dis (2008) 1.00
Phylogeography and epidemiological history of West Nile virus genotype 1a in Europe and the Mediterranean basin. Infect Genet Evol (2011) 1.00
The genotypic false positive rate determined by V3 population sequencing can predict the burden of HIV-1 CXCR4-using species detected by pyrosequencing. PLoS One (2013) 1.00